Intensive treatment of pseudomonas chest infection in cystic fibrosis: a comparison of tobramycin and ticarcillin, and netilmicin and ticarcillin.
Seventeen cystic fibrosis patients aged 3.1 years to 19.8 years had 30 courses of intensive treatment for relapse of their pseudomonas chest infection. The combination of netilmicin and ticarcillin was compared with tobramycin and ticarcillin in an open study. A significant subjective and objective improvement occurred in all patients. Pseudomonas was cleared temporarily from the sputum in 11 out of the 30 courses of treatment (37%). There was no significant difference between the netilmicin and tobramycin groups, nor evidence of sustained renal or ototoxicity. Intensive therapy of pseudomonas chest infection in cystic fibrosis patients is described in detail.
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003550:Cystic Fibrosis / Q000150:complications / Q000188:drug therapy*; D004338:Drug Combinations; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use*; D006801:Humans; D008176:Lung Volume Measurements; D008297:Male; D009428:Netilmicin / Q000627:therapeutic use*; D010406:Penicillins / Q000627:therapeutic use*; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000209:etiology; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000209:etiology; D013183:Sputum / Q000382:microbiology; D013982:Ticarcillin / Q000627:therapeutic use*; D014031:Tobramycin / Q000627:therapeutic use*
D004338:Drug Combinations; D005839:Gentamicins; D010406:Penicillins; D009428:Netilmicin; D013982:Ticarcillin; D014031:Tobramycin